Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Alrawashdh, Neda
McBride, Ali
Slack, Marion
Abraham, Ivo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136358
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Alrawashdh, Neda
    Alkhatib, Nimer
    McBride, Ali
    Persky, Daniel
    Abraham, Ivo
    BLOOD, 2018, 132
  • [2] Matching-adjusted indirect comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
    Cai, Ling
    Roos, Jack
    Miranda, Paulo A. P.
    Liljas, Bengt
    Rule, Simon
    Wang, Michael
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1552 - 1557
  • [3] Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Shah, Bijal
    Challagulla, Swetha
    Xu, Sheng
    Williams, Rhys
    Ren, Shijie
    Srivastava, Tushar
    Gautam, Raju
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S516 - S517
  • [4] Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/ Refractory Mantle Cell Lymphoma
    Gaitonde, Priyanka
    Cai, Ling
    de Miranda, Paulo
    Roos, Jack
    Rule, Simon
    Wang, Michael L.
    BLOOD, 2022, 140 : 3646 - 3647
  • [5] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [6] ECONOMIC EVALUATION OF IBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA IN MEXICO
    Carlos, F.
    Herrera, M.
    Salazar, A.
    Aguirre, A.
    Gonzalez-Michaca, L.
    VALUE IN HEALTH, 2016, 19 (03) : A249 - A249
  • [7] Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
    Tam, Constantine S.
    Opat, Stephen
    Simpson, David
    Cull, Gavin
    Munoz, Javier
    Phillips, Tycel J.
    Kim, Won Seog
    Rule, Simon
    Atwal, Siminder Kaur
    Wei, Rachel
    Novotny, William
    Huang, Jane
    Wang, Michael
    Trotman, Judith
    BLOOD ADVANCES, 2021, 5 (12) : 2577 - 2585
  • [8] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
    Song, Yuqin
    Zhou, Keshu
    Yang, Shenmiao
    Hu, Jianda
    Zou, Dehui
    Gao, Sujun
    Pan, Ling
    Wang, Tingyu
    Yang, Haiyan
    Zhang, Huilai
    Zhou, Daobin
    Ji, Jie
    Xu, Wei
    Feng, Ru
    Jin, Jie
    Lv, Fangfang
    Huang, Haiwen
    Fan, Xiaosi
    Xu, Sheng
    Zhu, Jun
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (04) : 606 - 616
  • [9] Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
    Yuqin Song
    Keshu Zhou
    Shenmiao Yang
    Jianda Hu
    Dehui Zou
    Sujun Gao
    Ling Pan
    Tingyu Wang
    Haiyan Yang
    Huilai Zhang
    Daobin Zhou
    Jie Ji
    Wei Xu
    Ru Feng
    Jie Jin
    Fangfang Lv
    Haiwen Huang
    Xiaosi Fan
    Sheng Xu
    Jun Zhu
    Investigational New Drugs, 2023, 41 : 606 - 616
  • [10] ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
    Hillmen, Peter
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Lamanna, Nicole
    O'Brien, Susan M.
    Qiu, Lugui
    Salmi, Tommi
    Hilger, James
    Wu, Kenneth
    Cohen, Aileen
    Huang, Jane
    Tam, Constantine S.
    FUTURE ONCOLOGY, 2020, 16 (10) : 517 - 523
12345